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THE EFFECTS OF NITRIC OXIDE ON MEDIATORS OF 
CARTILAGE METABOLISM IN HUMAN OA CARTILAGE 
DETECTED BY ANTIBODY MICROARRAY 
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E Moilanen 1,2 
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University of Tampere, Tampere, Finland; 2Research Unit, 
Tampere University Hospital, Tampere, Finland; 3 Coxa Hospital 
for Joint Replacement, Tampere, Finland 
Aim of the Study: In the pathogenesis of osteoarthritis (OA), 
the course of the destructive process in the cartilage is deter- 
mined by the balance between anabolic and catabolic mediators, 
and their regulators. Proinflammatory cytokine interleukin-1 (IL- 
l )  plays a central role in cartilage destruction and the destruc- 
tive effects of this cytokine are partly mediated by induced nitric 
oxide (NO) production. In the present study, we investigated se- 
cretion of 40 mediators related to cartilage metabolism (e.g. cy- 
tokines and destructive nzymes) by 80A cartilage samples with 
an antibody-based microarray. The role of NO on the production 
of these mediators in OA cartilage was investigated by using an 
iNOS inhibitor 1400W. 
Methods: Cartilage tissue was obtained from the leftover pieces 
of total knee replacement surgery from patients with OA. Cy- 
tokine and NO production was studied in organ culture to allow 
chondrocytes to live in their natural microenvironment and thus to 
maintain their characteristic phenotype. Custom Human Cytokine 
Antibody Array (Ray Biotech, Inc.) was used to measure relative 
expression levels of 40 cytokines and other inflammatory medi- 
ators in the culture medium. Results were considered significant 
when most of the OA samples showed over 20% change in the 
relative expression levels when compared to the respective con- 
trol. 
Results: OA cartilage secreted spontaneously 23 out of the 40 
measured mediators. Proinflammatory cytokine IL-11~ (4 ng/ml) 
enhanced production of 21 of these inflammatory mediators in 
OA cartilage along with increased NO production. Inhibition of NO 
production with a selective iNOS inhibitor 1400W (1 mM) resulted 
in enhancement of IL-10, IL-17, MMP-13 and TIMP-2 production, 
while the levels of leukemia inhibitory factor (LIF), MMP-2, MMP- 
10 and TGFI~ 2 were reduced. 
Conclusions: OA cartilage produces many of the mediators in- 
volved in the pathogenesis of OA. The ability of 1400W to en- 
hance levels of protective IL-10 and TIMP-2 and to reduce lev- 
els of destructive LIF, MMP-2 and MMP-10 points to the anti- 
inflammatory mechanisms that iNOS inhibitors may have in the 
treatment of OA. However, inhibition of NO production enhanced 
also the levels of catabolic IL-17 and MMP-13 and reduced the 
levels of anabolic TGFI~ 2. 
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INFLUENCE OF COLLAGEN HYDROLYSATE ON THE 
EXTRACELLULAR MATRIX METABOLISM OF HUMAN 
CHONDROCYTES 
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1CRI, Collagen Research Institute, Kiel, 2 Germany; Department 
of General Surgery and Traumatology, Klinikum Elmshorn, 
Elmshorn, Germany 
Aim of the study: Clinical studies have demonstrated the posi- 
tive effect of orally administered collagen hydrolysate in the treat- 
ment of osteoarthritis. The objective of this study was to inves- 
tigate the effect of a specific collagen hydrolysate (CH) on the 
biosynthesis of human chondrocytes in a cell culture model. 
Methods: The experiments were performed using monolayer cul- 
tures and 3D alginate cultures of human femoral head chondro- 
cytes. Human articular cartilage was collected from patients that 
had undergone primary hip replacement after femoral neck frac- 
tures. Presence of osteoarthritis in the operated joint was ex- 
cluded on the basis of x-ray examinations and patient interviews. 
Chondrocytes were isolated from the cartilage within 3 hours af- 
ter surgery and cultured under reduced oxygen conditions. 
The CH used in the investigation had a mean MW of 3.3 kDa, with 
fragments predominantly representing degraded type I collagen. 
To start the experiment, culture medium of the isolated chondro- 
cytes was supplemented with CH and at the end of the observa- 
tion period type II collagen biosynthesis was quantified by means 
of ELISA technique. The results were confirmed by immunocyto- 
chemical detection of type II collagen and by analyzing the incor- 
poration of 14C-proline into matrix proteins. Moreover, the amount 
of pericellular proteoglycans was determined by a colorimetric 
assay and protease activity in the culture media was assayed by 
means of gelatine-substrate zymography. 
Results: Supplementation of the culture medium with CH led to a 
dose-dependent, statistically significant (p<0.05) increase of type 
II collagen biosynthesis in human chondrocytes compared to the 
control cells cultured in basal culture medium. At a concentration 
of 0.5 mg CH/ml a maximum stimulation of type II collagen syn- 
thesis of more than 25% was observed. Moreover, the amount 
of pericellular proteoglycans was also significantly (p<0.05) in- 
creased after administration of CH, whereas the presence of ex- 
tracellular CH had no significant effect on the protease activity of 
human chondrocytes compared to the untreated controls. 
Conclusion: These results indicate a stimulatory effect of CH 
on the synthesis of extracellular matrix macromolecules by hu- 
man chondrocytes, whereas protease activity of the cells is not 
affected by CH treatment. Based on these this data, we have pro- 
vided evidence that CH might contribute to reduce degenerative 
alterations of the extracellular matrix and thus might be of thera- 
peutic relevance in the treatment and prevention of osteoarthritis. 
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Aims: To compare the expression of the type I nitric oxide syn- 
thase (NOS I) in normal and osteoarthritic human chondrocytes 
and to study its regulation by anabolic growth factors and pro- 
inflammatory cytokines. 
Methods: Chondrocytes were isolated from the cartilage of the 
femoral condyles obtained from 8 osteoarthritis (OA) patients 
undergoing total knee replacement surgery and from 2 cadav- 
eric donors without macroscopic signs of arthritis. After isola- 
tion, chondrocytes were plated in 6-well plates at high density 
to prevent dedifferentiation. NOS I protein levels were evaluated 
in the cytoplasmic extracts by Western blot with a rabbit anti- 
human NOS I antibody (Abcam Ltd., Cambridge, UK), followed 
by a goat anti-rabbit IgG-alkaline phosphatase-conjugated anti- 
body. Immunoreactive complexes were detected by chemifluo- 
rescence using the ECF reagent (Amersham Biosciences, Buck- 
inghamshire, UK). Fluorescence was detected with a Storm 840 
fluorescence scanner (Amersham Biosciences). 
Results: NOS I protein was detected in the cytoplasmic extracts 
from the normal donors and from one OA sample. The other 7 
OA samples had no detectable NOS I protein. Treatment of the 
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chondrocyte cultures, either from the normal donors or from the 
OA patients, with I L-1 I~ (10 ng/ml, incubation periods ranging from 
5 min to 16 h), TNF-~ (20 ng/ml, 6 h), TGF-I~ (10 ng/ml, 2, 6 and 
16 h-incubation periods) or IGF-1 (100 ng/ml, 6 h) did not change 
NOS I protein levels relatively to the respective controls. 
Conclusions: The results obtained show that OA chondrocytes 
are deficient in NOS I relatively to normal cells and also indicate 
that this protein is not regulated by any of the anabolic or catabolic 
stimuli n the conditions tested. Our previous results showed that, 
in bovine chondrocytes, NOS I is rapidly degraded in response to 
IL-1 and that NO inhibits IL-1 -induced NF-KB activation and iNOS 
expression, indicating that NO participates in a regulatory mech- 
anism that prevents accidental or inappropriate NF-KB activation. 
The absence of the NOS I protein in human OA chondrocytes, 
reported here, suggests that the regulatory mechanism identified 
in normal bovine chondrocytes does not opperate in human OA 
chondrocytes. Thus, the absence of NOS I may contribute to the 
impaired regulation of NF-KB activation and of the expression of 
its target genes, namely, several inflammation-related genes and 
matrix metalloproteinases that contribute to the development and 
progression of arthritic diseases. 
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OSTEOARTHRIT IC CHONDROCYTES AND SYNOVIAL 
F IBROBLAST IN CULTURE 
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Few structure-modifying drugs have been used to date for OA 
treatment, and most commonly used medications are symptom- 
modifying drugs, such as NSAIDs. Although both treatments have 
been shown to be effective for improving pain and disability, their 
effects on cartilage and synovial metabolism remain poorly stud- 
ied. 
Aim of the study: To compare the effect of glucosamine sulfate 
(GS) to that seen for different anti-OA drugs, such as NSAI Ds and 
other nutraceuticals on the activation of several proinflammatory 
and structural mediators in OA chondrocytes and synoviocytes in 
culture. 
Methods: Chondrocytes and synoviocytes were obtained from 
joint specimens of OA patients who underwent otal knee replace- 
ment. Using quiescent cells stimulated with 10 U/ML IL-11~, the ef- 
fects of GS (1 mg/ml), meloxicam (MXC, 10-6M), diclofenac (DCF, 
10-6M), indomethacin (IND, 10-6M), chondroitin sulphate (CS, 
1 mg/ml), diacerhein (DC, 10-5M), and N-acetylcysteine (NAC, 
2 mM) on prostaglandin (PG) E2 production, cyclooxigenase- 
2 (COX-2) expression, nitric oxide (NO) synthesis, metallopro- 
teinase (MMP)-I and MMP-13 presence and nuclear factor kappa 
B (NFKB) activation were studied. 
Results: With IL-11~ stimulation, an increased presence of all of 
these mediators was noted, except for NO synthesis in synovio- 
cytes. After stimulation, PGE2 synthesis was significantly inhib- 
ited by GS (up to 60%) and NSAIDs (100%) in both cell types, 
and also by DC (45%) in chondrocytes and by NAC (65%) in 
synoviocytes. COX-2 synthesis, measured by western-blot tech- 
niques, was also inhibited in both cell types by incubation with 
GS (up to 60%) or NSAIDs (up to 40%), while NAC (50%) also 
diminished COX-2 in synoviocytes. In relation to the increase in 
NO synthesis in chondrocytes evoked by IL-11~, only GS (75%), 
DC (30%) and CS (20%) were able to inhibit it, and no effect was 
noted for NSAIDs or NAC. One of the possible cellular mecha- 
nisms involved in the activation of these proinflammatory events 
has also been studied. NFKB activation was only inhibited by 
GS (60%), DC (75%) and DCF (75%) in chondrocytes, and by 
GS (45%), DC (69%), CS (65%)and DCF (60%) in synoviocytes. 
MMP-1 and -13 activation were inhibited only in chondrocytes 
by GS (65% and 75%, respectively). Between other nutraceuti- 
cals, only CS (60%) diminished MMP-1 activity in chondrocytes. 
However, NSAID presence did not modify or even super-induced 
MMP1 and -13 synthesis in both cell types. 
Conclusion: GS inhibits the synthesis of proinflammatory and 
structural mediators in OA chondrocytes and synoviocytes tim- 
ulated by IL-11~. The presence of other nutraceticals only partially 
controlled some of these mediators. NSAIDs were able to signif- 
icantly inhibit proinflammatory pathways, while structural media- 
tors were unchanged or even activated. Our study supports the 
role of GS as a symptom and structure-modifying drug. 
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INFLUENCE OF PLATELET RICH PLASMA IN HUMAN 
CHONDROCYTE 
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Aim of Study: The aim of the present study is to investigate the 
effects of platelet rich plasma (PRP) on proliferation and rediffer- 
entiation of cultivated human chondrocytes. 
Methods: Whole blood and knee joint cartilage were supplied 
from 10 adult donors after informed consent. Chondrocytes were 
isolated by enzyme digestion from cartilage and suspended nu- 
trient mixture medium with 10% fetal bovine serum (FBS). When 
cultured dishes became near confluent, cells were passed only 
one time. Blood was drawn into a bag containing anticoagulant 
and centrifuged twice to obtain PRP. By mixing calcium gluconate 
and thrombin to PRP, platelets released growth factors from their 
granule and PRP gel was obtained. MTT assay was used for 
the quantitative determination of cellular proliferation. We inves- 
tigated the effect of different PRP concentrations on chondro- 
cyte proliferation and also performed a time course experiment 
to establish a growth curve of cells cultivated in control condi- 
tion (30% platelet poor plasma) or in 30% PRP. All MTT assays 
were performed using serum-free medium. Redifferentiation of 
cultivated chondrocyte is associated with increased glycosamino- 
glycans (GAGs) and type II collagen expression. Alcian blue and 
anti-type II collagen antibodies were used for histochemical and 
immunohistochemical examinations to analyze the influence of 
PRP on redifferentiation. 
Results: Cell proliferation of human chondrocytes was sensitive 
to PRP. The increase was dose dependent, and MTT values in- 
creased as the percentage of PRP increased. Thirty percent PRP 
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Fig. 1. MTT assay of human chondrocyte. 
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